Status and phase
Conditions
Treatments
About
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
Full description
This is a Phase II, multicenter, single-arm, open label study of AB-106 in the Chinese patients with advanced NSCLC harboring ROS1 fusion gene.The study will be divided into two stages. First stage (Stage I) is to determine the clinical optimal dose of AB-106, which will be evaluated at two dose levels (400 mg QD and 600mg QD), and the safety, tolerability and pharmacokinetics of AB-106 will be evaluated at the same time; Second stage (Stage II) is to evaluate the efficacy and safety of AB-106 at the clinical optimal dose determined from Stage I. It is expected that 6 patients with advanced NSCLC harboring ROS1 fusion will be enrolled in the first stage. About 167 patients with ROS1 fusion will be enrolled in the second stage and divided into two treatment cohorts (Cohort A & Cohort B). It is planned to enroll about 106 ROS1-TKI treatment naïve patients in Cohort A and about 67 crizotinib pre-treated patients in Cohort B. AB-106 will be administered 600mg once daily in 21-day cycles. Patients will continue with the study treatment until progression of disease as determined by the investigator. The tumor response evaluation will be conducted in every 6 weeks in the first 8 cycles, and then every 12 weeks until progression of disease as determined by the investigator. The long-term survival follow up will be conducted every 12 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients must meet all of the following criteria to be eligible for enrollment into the study:
Adequate organ functions defined by the following criteria:
Exclusion criteria
Patient presenting with any of the following criteria will not be included in the study:
Primary purpose
Allocation
Interventional model
Masking
173 participants in 1 patient group
Loading...
Central trial contact
AnHeart Clinical Development
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal